Neoadjuvant hormonal therapy and radical prostatectomy in the treatment of clinical stage T3 cancer of the prostate.
We evaluated the results of a treatment protocol that consisted of neoadjuvant hormonal therapy followed by radical retropubic prostatectomy (RRP) for clinical stage T3 (cT3) prostate cancer. Sixty-six patients with cT3 prostate cancer underwent staging procedures that included metastatic work-up and evaluation under anesthesia. Neoadjuvant hormonal treatment was given for 3 to 6 months, followed by re-evaluation under anesthesia. Patients considered to have a resectable prostate following neoadjuvant treatment underwent operation. Disease-free survival [prostate-specific antigen (PSA) < 0.1 ng/ml] was calculated by the Kaplan-Meier method for cT3 patients and for a group of patients with clinical stage 1 and 2 disease (cT1-2), who underwent RRP without neoadjuvant hormonal therapy. Patients with pT3 disease in both groups received early adjuvant radiation treatment. Patients in the cT3 group who were not clinically downstaged were treated with radiation. Patients with positive lymph nodes continued hormonal therapy. The pretreatment PSA for the cT3 group was 43.6 ± 55.6 ng/ml, and 10.64 ± 7.18 ng/ml for the cT1-2 group (p < 0.05). Of 66 cT3 patients, 53 (80%) were clinically downstaged and operated on and 47 (71%) underwent RRP. At 36 months, there was no significant difference in the PSA relapse rate between these two groups; both had significantly lower rates than did patients in the cT3 without RRP. At 48 months, 79% (21 patients) of the patients in the cT3-RRP group were disease free compared with 50% of those in the cT3 without RRP (4 patients). Neoadjuvant hormonal therapy for stage cT3 prostate cancer selects patients whose cancer can be controlled by RRP for an extended period of time.